Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Bevacizumab in Second-line Non-squamous NSCLC
NCT00749567Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jul 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Started Jul 2008; status: terminated.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00749567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00749567.